ArticleNature communications2021
Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Genetic susceptibility, risk prediction, and druggable targets for oropharyngeal cancer: a UK Biobank study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Identification of Immune&Driver Molecular Subtypes Optimizes Immunotherapy Strategies for Gastric Cancer.International journal of molecular sciences · 2026Article
- The impact of gut microbiota on cervical cancer and precancerous lesions: neglected status, mechanisms, challenges, and a call to action.Frontiers in immunology · 2026Review
- Cross-ancestral GWAS identifies 29 variants across head and neck cancer subsites.Nature communications · 2025Article
- IgG and IgM Seroreactivity Against Natural HPV16 Infection and HLA-DRB1 and -DQB1 Polymorphism.Journal of medical virology · 2025Article
- VOYAGER: an international consortium investigating the role of human papilloma virus and genetics in oral and oropharyngeal cancer risk and survival.medRxiv : the preprint server for health sciences · 2025Article
- Genetic, clinical, lifestyle and sociodemographic risk factors for head and neck cancer: A UK Biobank study.PloS one · 2025Article
- Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization study.Nature communications · 2024Article
- Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.Molecular carcinogenesis · 2024Article
- A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers.International journal of cancer · 2023Article
- The tumor ecosystem in head and neck squamous cell carcinoma and advances in ecotherapy.Molecular cancer · 2023Review
- Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.Investigational new drugs · 2023Article
- Immunogenetic Determinants of Susceptibility to Head and Neck Cancer in the Million Veteran Program Cohort.Cancer research · 2023Article
- Outcome differences in HPV-driven head and neck squamous cell carcinoma attributable to altered human leukocyte antigen frequencies.Frontiers in oncology · 2023Article
- Assessment of genetic susceptibility to multiple primary cancers through whole-exome sequencing in two large multi-ancestry studies.BMC medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 20 institutions in 11 countries.
Aida Ferreiro-IglesiasSection of Genetics, Genetic Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France. ferreiroa@iarc.fr.ORCID 0000-0002-1458-7936
James D McKaySection of Genetics, Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.
Nicole BrennerInfections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-7690-4925
Shama ViraniSection of Genetics, Genetic Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0002-1163-432X
Corina LesseurSection of Genetics, Genetic Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0001-6744-6750
Valerie GaborieauSection of Genetics, Genetic Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.
Andy R NessNational Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Bristol, UK.
Rayjean J HungProsserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.ORCID 0000-0002-4486-7496
Geoffrey LiuLunenfeld-Tanenbaum Research Institute of Sinai Health System, University of Toronto, Toronto, ON, Canada.
Brenda DiergaardeDepartment of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Andrew F OlshanDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Neil HayesDivision of Medical Oncology and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.ORCID 0000-0001-6203-7771
Mark C WeisslerDepartment of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, Chapel Hill, NC, USA.
Lea SchroederInfections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Noemi BenderInfections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michael PawlitaInfections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-4720-8306
Steve ThomasBristol Dental School, University of Bristol, Bristol, UK.
Miranda PringBristol Dental School, University of Bristol, Bristol, UK.
Tom DuddingBristol Dental School, University of Bristol, Bristol, UK.ORCID 0000-0003-3756-040X
Beatriz KanterewiczUPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Robert FerrisUPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Sera ThomasProsserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
Yonathan BrhaneProsserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
Virginia Díez-ObreroOncology Data Analytics Program, Catalan Institute of Oncology (ICO), Barcelona, Spain.
Maja MilojevicSection of Genetics, Genetic Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0002-8248-8884
Karl Smith-ByrneSection of Genetics, Genetic Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0002-1932-7463
Daniela MariosaSection of Genetics, Genetic Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0001-8181-1419
Mattias J JohanssonSection of Genetics, Genetic Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0002-3116-5081
Rolando HerreroSection of Early Detection and Prevention, Prevention and Implementation Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.
Stefania BocciaSection of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Roma, Italy.
Gabriella CadoniDepartment of Head and Neck Surgery, Institute of Clinical Otorhinolaryngology, Università Cattolica del Sacro Cuore, Roma, Italy.
Martin LackoDepartment of Otorhinolaryngology, Head and Neck Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.ORCID 0000-0003-2868-4822
Ivana HolcátováInstitute of Hygiene and Epidemiology, Prague, Czech Republic.
Wolfgang AhrensUniversity Bremen, Bremen, Germany.
Pagona LagiouSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Areti LagiouSchool of Public Health, University of West Attica, Athens, Greece.
Jerry PoleselNational Cancer Institute, IRCCS, Aviano, Italy.ORCID 0000-0001-9381-1520
Lorenzo SimonatoUniversity of Padova, Padova, Italy.
Franco MerlettiCeRMS and University of Turin, Turin, Italy.
Claire M HealyTrinity College School of Dental Science, Dublin, Ireland.
Bo T HansenCancer Registry of Norway, Oslo, Norway.
Mari NygårdDepartment of Research, Cancer Registry of Norway, Oslo, Norway.
David I ConwaySchool of Medicine, Dentistry, and Nursing, University of Glasgow, Glasgow, UK.
Sylvia WrightQueen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK.
Tatiana V MacfarlaneUniversity of Aberdeen, Aberdeen, UK.
Max RobinsonCentre for Oral Health Research, Newcastle University, Newcastle, UK.ORCID 0000-0003-4491-6865
Laia AlemanyCatalan Institute of Oncology/IDIBELL, Barcelona, Spain.
Antonio AgudoCatalan Institute of Oncology/IDIBELL, Barcelona, Spain.
Ariana ZnaorCancer Surveillance Section, International Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0002-5849-4782
Christopher I AmosDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
Tim WaterboerInfections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Paul BrennanSection of Genetics, Genetic Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France. gep@iarc.fr.ORCID 0000-0002-0518-8714
Centre international de recherche sur le cancer · FRGerman Cancer Research Center · DELunenfeld-Tanenbaum Research Institute · CAUniversity Of Bristol Dental Hospital · GBCancer Registry of Norway · NOInstitut d'Investigació Biomédica de Bellvitge · ESUniversità Cattolica del Sacro Cuore · ITUniversity of North Carolina at Chapel Hill · USUPMC Hillman Cancer Center · USBaylor College of Medicine · USInstitut Català d'Ornitologia · ESIstituti di Ricovero e Cura a Carattere Scientifico · ITMaastricht University · NLNational and Kapodistrian University of Athens · GRNewcastle University · GBNHS Greater Glasgow and Clyde · GBTrinity College Dublin · IEUniversity of Aberdeen · GBUniversity of Bremen · DEUniversity of Glasgow · GB
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MWILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe · 2004 to 2026
$49.6MGene Environment Interaction in Head and Neck CancerR01CA090731 · NCI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI OLSHAN, ANDREW · 2001 to 2005
$4.6MGENETICS OF TOBACCO AND ALCOHOL RELATED CANCERSR01CA092039 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI BRENNAN, PAUL JOSEPH · 2003 to 2010
$3.6MThe role of germline and somatic DNA mutations in oral and oropharyngeal cancersR01DE025712 · NIDCR · INTERNATIONAL AGENCY FOR RES ON CANCER · PI BRENNAN, PAUL JOSEPH, DIERGAARDE, BRENDA B. · 2017 to 2021
$3.3MCancer Research UK C18281/A19169Department of Health RP-PG-0707-10034Medical Research Council MR/N005872/1NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA097190NCI NIH HHS R01 CA090731NCI NIH HHS R01 CA092039NIDCR NIH HHS R01 DE025712World Health Organization 001
Abstract
Although several oropharyngeal cancer (OPC) susceptibility loci have been identified, most previous studies lacked detailed information on human papillomavirus (HPV) status. We conduct a genome-wide analysis by HPV16 serology status in 4,002 oral cancer cases (OPC and oral cavity cancer (OCC)) and 5,256 controls. We detect four susceptibility loci pointing to a distinct genetic predisposition by HPV status. Our most notable finding in the HLA region, that is now confirmed to be specific of HPV(+)OPC risk, reveal two independent loci with strong protective effects, one refining the previously reported HLA class II haplotype association. Antibody levels against HPV16 viral proteins strongly implicate the protective HLA variants as major determinants of humoral response against L1 capsid protein or E6 oncoprotein suggesting a natural immune response against HPV(+)OPC promoted by HLA variants. This indicates that therapeutic vaccines that target E6 and attenuate viral response after established HPV infections might protect against HPV(+)OPC.
Indexed as
Immunity, HumoralAgedAntibodies, ViralCapsid ProteinsCase-Control StudiesFemaleGene ExpressionGenetic Predisposition to DiseaseGenome-Wide Association StudyHaplotypesHLA AntigensHuman papillomavirus 16HumansMaleMeta-Analysis as TopicMiddle AgedAntibodies, ViralCapsid ProteinsE6 protein, Human papillomavirus type 16HLA AntigensOncogene Proteins, ViralRepressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.